San Antonio — Effectively pulling off a change in management is no small feat. For Invictus Medical, it may be even more difficult because the departure of its long-time CEO, Tom Roberts, occurred at the same time the company is... Read more »
A startup’s struggle to stand out in a crowded industry can sometimes get a lift from a distinguishing product feature or the decision to focus on solving a specific problem.
That theory will be put to the test with Rize.... Read more »
The field of cancer immunotherapy is so crowded and competitive these days that many companies are trying to stand by touting a next-generation approach. The latest company to do so is Oncorus, a Cambridge, MA-based startup that this morning closed a $57 million... Read more »
Zimmer Biomet is staking out territory in the fast-growing robotic surgery market by acquiring Medtech, a France-based company that has already commercialized robotic systems used in brain and spinal procedures.
Warsaw, IN-based Zimmer Biomet (NYSE: ZBH) paid an estimated $77... Read more »
Just when the online lending scene seemed mired in doldrums and doubt, New York-based CommonBond landed several deals to shake things up.
The company announced on Tuesday it raised $30 million, in a Series C equity round led by Neuberger Berman... Read more »
In what could be another sign of a shakeout in the cybersecurity industry, Carbon Black says today it has acquired fellow Boston-area security firm Confer Technologies. The deal has closed, but financial terms weren’t given.
Both companies focus on endpoint... Read more »
It’s getting harder and harder to stand out in the increasingly crowded cancer immunotherapy field. But with a wide-ranging alliance being announced this morning, three-year-old Jounce Therapeutics has been able to make its mark.
The Cambridge, MA-based company has inked a... Read more »
Former Epizyme CEO Robert Gould is back with a new startup. A year after stepping down as the CEO of Cambridge, MA-based Epizyme, Gould has re-emerged to lead another Cambridge company, Fulcrum Therapeutics, which has secured a massive $55 million Series... Read more »